Inflammation, infection, cancer and all that...the role of paraoxonases

Advances in Experimental Medicine and Biology

Volumn 824, Issue , 2014, Pages 33-41

  Devarajan, Asokan ^a   Shih, Diana ^a   Reddy, Srinivasa T ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antioxidants; Atherosclerosis; Cancer; Endoplasmic reticulum stress; Inflammation; Paraoxonase 1; Paraoxonase 2; Paraoxonase 3; Quorum sensing

Indexed keywords

ARYLDIALKYLPHOSPHATASE; ARYLDIALKYLPHOSPHATASE 1; ARYLDIALKYLPHOSPHATASE 2; HIGH DENSITY LIPOPROTEIN; PARAOXONASE 3; UNCLASSIFIED DRUG;

ARTICLE; ATHEROSCLEROSIS; CELL MEMBRANE; DIABETES MELLITUS; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENDOPLASMIC RETICULUM STRESS; GENE FUNCTION; GENE OVEREXPRESSION; HUMAN; INFECTION; INFLAMMATION; MITOCHONDRION; NEOPLASM; NONHUMAN; OXIDATIVE STRESS; PON1 GENE; PON2 GENE; PON3 GENE; PRIORITY JOURNAL; PROTEIN FUNCTION; PSEUDOMONAS INFECTION; QUORUM SENSING;

EID: 84934436045     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-3-319-7320-0_5     Document Type: Article

References (55)

1. Reddy ST, Devarajan A, Bourquard N, Shih D, Fogelman AM. Is it just paraoxonase 1 or are other members of the paraoxonase gene family implicated in atherosclerosis? Curr Opin Lipidol. 2008;19:405-8.
2. She ZG, Chen HZ, Yan Y, Li H, Liu DP. The human paraoxonase gene cluster as a target in the treatment of atherosclerosis. Antioxid Redox Signal. 2012; 16:597-632.
3. Primo-Parmo SL, Sorenson RC, Teiber J, La Du BN. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics. 1996;33:498-507.
4. Draganov DI, La Du BN. Pharmacogenetics of paraoxonases: a brief review. Naunyn Schmiedebergs Arch Pharmacol. 2004;369:78-88.
5. Aldridge WN. Serum esterases I. Two types of esterase (A and B) hydrolysing p-nitrophenyl acetate, propionate and butyrate and a method for their determination. Biochem J. 1953;53:110-7.
6. Aldridge WN. Serum esterases II. An enzyme hydrolyzing diethyl p-nitrophenyl acetate (E600) and its identity with the A-esterase of mammalian sera. Biochem J. 1953;53:117-24.
7. Bhattacharyya T, Nicholls SJ, Topol EJ, Zhang R, Yang X, Schmitt D, et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA. 2008;299:1265-76.
8. Stevens RC, Suzuki SM, Cole TB, Park SS, Richter RJ, Furlong CE. Engineered recombinant human paraoxonase 1 purified from Escherichia coli protects against organophosphate poisoning. Proc Natl Acad Sci U S A. 2008;105:12780-4.
9. Stoltz DA, Ozer EA, Taft PJ, Barry M, Liu L, Kiss PJ, et al. Drosophila are protected from Pseudomonas aeruginosa lethality by transgenic expression of paraoxonase-1 J Clin Invest. 2008;118:3123-31.
10. Witte I, Altenhöfer S, Wilgenbus P, Amort J, Clement AM, Pautz A, et al. Beyond reduction of atherosclerosis: PON2 provides apoptosis resistance and stabilizes tumor cells. Cell Death Dis. 2011;13(2):e112.
11. Schweikert EM, Devarajan A, Witte I, Wilgenbus P, Amort J, Förstermann U, et al. PON3 is upregulated in cancer tissues and protects against mitochondrial superoxide-mediated cell death. Cell Death Differ. 2012;19:1549-60.
12. Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S, et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature. 1998;394:284-7.
13. Shih DM, Xia YR, Wang XP, Miller E, Castellani LW, Subbanagounder G, et al. Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J Biol Chem. 2000;275:17527-35.
14. Tward A, Xia YR, Wang XP, Shi YS, Park C, Castellani LW, et al. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation. 2002;106:484-90.
15. Devarajan A, Bourquard N, Hama S, Navab M, Grijalva VR, Morvardi S, et al. Paraoxonase 2 defi- ciency alters mitochondrial function and exacerbates the development of atherosclerosis. Antioxid Redox Signal. 2011;14:341-51.
16. Shih DM, Xia YR, Wang XP, Wang SS, Bourquard N, Fogelman AM, et al. Decreased obesity and atherosclerosis in human paraoxonase 3 transgenic mice. Circ Res. 2007;100:1200-7.
17. She ZG, Zheng W, Wei YS, Chen HZ, Wang AB, Li HL, et al. Human paraoxonase gene cluster transgenic overexpression represses atherogenesis and promotes atherosclerotic plaque stability in ApoE-null mice. Circ Res. 2009;104:1160-8.
18. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest. 1998;101:1581-90.
19. Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM, et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest. 1995;96:2882-91.
20. Deakin SP, Bioletto S, Bochaton-Piallat ML, James RW. HDL-associated PON1 can redistribute to cell membranes and influence sensitivity to oxidative stress. Free Radic Biol Med. 2011;50:102-9.
21. Aviram M. Atherosclerosis: cell biology and lipoproteins - paraoxonases protect against atherosclerosis and diabetes development. Curr Opin Lipidol. 2012; 23:169-71.
22. Kim DS, Marsillach J, Furlong CE, Jarvik GP. Pharmacogenetics of paraoxonase activity: elucidating the role of high-density lipoprotein in disease. Pharmacogenomics. 2013;14:1495-515.
23. Huang Y, Wu Z, Riwanto M, Gao S, Levison BS, Gu X, et al. Myeloperoxidase, paraoxonase-1, and HDL form a functional ternary complex. J Clin Invest. 2013;123:3815-28.
24. Mackness M, Mackness B. Targeting paraoxonase- 1 in atherosclerosis. Expert Opin Ther Targets. 2013;17:829-37.
25. Tang WH, Hartiala J, Fan Y, Wu Y, Stewart AF, Erdmann J, et al. Clinical and genetic association of serum paraoxonase and arylesterase activities with cardiovascular risk. Arterioscler Thromb Vasc Biol. 2012;32:2803-12.
26. Charles-Schoeman C, Lee YY, Shahbazian A, Gorn AH, Fitzgerald J, Ranganath VK, et al. Association of paraoxonase 1 gene polymorphisms and enzyme activity with carotid plaque in rheumatoid arthritis. Arthritis Rheum. 2013;65:2765-72.
27. Garcia-Heredia A, Marsillach J, Rull A, Triguero I, Fort I, Mackness B, et al. Paraoxonase-1 inhibits oxidized low-density lipoprotein-induced metabolic alterations and apoptosis in endothelial cells: a non directed metabolomic study. Mediat Inflamm. 2013;2013:156053.
28. Garcia-Heredia A, Kensicki E, Mohney RP, Rull A, Triguero I, Marsillach J, et al. Paraoxonase-1 defi- ciency is associated with severe liver steatosis in mice fed a high-fat high-cholesterol diet: a metabolomic approach. J Proteome Res. 2013;12:1946-55.
29. Jarvik GP, Rozek LS, Brophy VH, Hatsukami TS, Richter RJ, Schellenberg GD, et al. Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1(192) or PON1(55) genotype. Arterioscler Thromb Vasc Biol. 2000;120:2441-7.
30. Mackness B, Durrington P, McElduff P, Yarnell J, Azam N, Watt M, et al. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation. 2003;107:2775-9.
31. Tang WH, Wu Y, Mann S, Pepoy M, Shrestha K, Borowski AG, et al. Diminished antioxidant activity of high-density lipoprotein-associated proteins in systolic heart failure. Circ Heart Fail. 2011;4:59-64.
32. Aviram M, Vaya J. Paraoxonase 1 activities, regulation, and interactions with atherosclerotic lesion. Curr Opin Lipidol. 2013;24:339-44.
33. Besler C, Heinrich K, Rohrer L, Doerries C, Riwanto M, Shih DM, et al. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J Clin Invest. 2011;121:2693-708.
34. Hazen SL, Heinecke JW. 3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. J Clin Invest. 1997;99:2075-81.
35. Zhang R, Brennan ML, Shen Z, MacPherson JC, Schmitt D, Molenda CE, et al. Myeloperoxidase functions as a major enzymatic catalyst for initiation of lipid peroxidation at sites of inflammation. J Biol Chem. 2002;277:46116-22.
36. Ng CJ, Bourquard N, Grijalva V, Hama S, Shih DM, Navab M, et al. Paraoxonase-2 deficiency aggravates atherosclerosis in mice despite lower apolipoprotein- B- containing lipoproteins: anti-atherogenic role for paraoxonase-2. J Biol Chem. 2006;281:29491-500.
37. Mabile L, Meilhac O, Escargueil-Blanc I, Troly M, Pieraggi MT, Salvayre R, et al. Mitochondrial function is involved in LDL oxidation mediated by human cultured endothelial cells. Arterioscler Thromb Vasc Biol. 1997;17:1575-82.
38. Altenhöfer S, Witte I, Teiber JF, Wilgenbus P, Pautz A, Li H, et al. One enzyme, two functions: PON2 prevents mitochondrial superoxide formation and apoptosis independent from its lactonase activity. J Biol Chem. 2010;6(285):24398-403.
39. Ng CJ, Wadleigh DJ, Gangopadhyay A, Hama S, Grijalva VR, Navab M, et al. Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J Biol Chem. 2001;276:44444-9.
40. Ohnishi T, Trumpower BL. Differential effects of antimycin on ubisemiquinone bound in different environments in isolated succinate. Cytochrome c reductase complex. J Biol Chem. 1980;255:3278-84.
41. Kim SB, Berdanier CD. Oligomycin sensitivity of mitochondrial F(1)F(0)-ATPase in diabetes-prone BHE / Cdb rats. Am J Physiol. 1999;277:E702-7.
42. Horke S, Witte I, Wilgenbus P, Krüger M, Strand D, Förstermann U. Paraoxonase-2 reduces oxidative stress in vascular cells and decreases endoplasmic reticulum stress-induced caspase activation. Circulation. 2007;17(115):2055-64.
43. Horke S, Witte I, Wilgenbus P, Altenhöfer S, Krüger M, Li H, et al. Protective effect of paraoxonase-2 against endoplasmic reticulum stress-induced apoptosis is lost upon disturbance of calcium homoeostasis. Biochem J. 2008;416:395-405.
44. Devarajan A, Grijalva VR, Bourquard N, Meriwether 3rd D, Imaizumi S, Shin BC, et al. Macrophage paraoxonase 2 regulates calcium homeostasis and cell survival under endoplasmic reticulum stress conditions and is sufficient to prevent the development of aggravated atherosclerosis in paraoxonase 2 deficiency/apoE(-/-) mice on a western diet. Mol Genet Metab. 2012;107:416-27.
45. Shih DM, Xia YR, Yu JM, Lusis AJ. Temporal and tissue-specific patterns of PON3 expression in mouse: in situ hybridization analysis. Adv Exp Med Biol. 2009;660:73-87.
46. Reddy ST, Wadleigh DJ, Grijalva V, Ng C, Hama S, Gangopadhyay A, et al. Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids. Arterioscler Thromb Vasc Biol. 2001;21:542-7.
47. Draganov DI. Lactonases with organophosphatase activity: structural and evolutionary perspectives. Chem Biol Interact. 2010;187:370-2.
48. Draganov DI, Teiber JF, Speelman A, Osawa Y, Sunahara R, La Du BN. Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J Lipid Res. 2005;46:1239-47.
49. Shiner EK, Rumbaugh KP, Williams SC. Interkingdom signaling: deciphering the language of acyl homoserine lactones. FEMS Microbiol Rev. 2005;29:935-47.
50. Chun CK, Ozer EA, Welsh MJ, Zabner M, Greenberg EP. Inactivation of a Pseudomonas aeruginosa quorum- sensing signal by human airway epithelia. Proc Natl Acad Sci U S A. 2004;101:3587-90.
51. Stoltz DA, Ozer EA, Ng CJ, Yu JM, Reddy ST, Lusis A, et al. Paraoxonase-2 deficiency enhances Pseudomonas aeruginosa quorum sensing in murine tracheal epithelia. Am J Physiol Lung Cell Mol Physiol. 2007;292:L852-60.
52. Devarajan A, Bourquard N, Grijalva VR, Gao F, Ganapathy E, Verma J, et al. Role of PON2 in innate immune response in an acute infection model. Mol Genet Metab. 2013;110:362-70.
53. Kim JB, Xia YR, Romanoski CE, Lee S, Meng Y, Shi YS, et al. Paraoxonase-2 modulates stress response of endothelial cells to oxidized phospholipids and a bacterial quorum-sensing molecule. Arterioscler Thromb Vasc Biol. 2011;31:2624-33.
54. Schweikert EM, Amort J, Wilgenbus P, Förstermann U, Teiber JF, Horke S. Paraoxonases-2 and -3 are important defense enzymes against Pseudomonas aeruginosa virulence factors due to their anti- oxidative and anti-inflammatory properties. J Lipids. 2012;2012: 352857.
55. Witte I, Foerstermann U, Devarajan A, Reddy ST, Horke S. Protectors or traitors: the roles of PON2 and PON3 in atherosclerosis and cancer. J Lipids. 2012;2012:342806.